PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
New specialty drug benefits research shows growing focus on medical-benefit drugs, rising interest in trading rebates for utilization controls, and increasing scrutiny of PBMs’ management…
A newly-initiated specialty medication costing more than $20,000 monthly went unnoticed by traditional reporting for an employer until it was identified by the PSG team…
Rethinking What “Data-Driven Strategy” Means in Pharmacy Benefits Key Points Many leaders use data to validate strategy, but the greatest value emerges when analytics become…
PSG Helps Execute Your Modular PBA Goals A Modular PBA model gives payers the flexibility to design pharmacy benefits around their specific goals, systems, and…
An Overview of Regulatory and Legislative Updates For Plan Sponsors Key Points The ESI settlement creates new options for plan sponsors, but few protections apply…
Will Additional SMA Gene Therapies Affect Payers’ Budgets? Key Points: SMA treatment has shifted from supportive care to high-cost disease-modifying and gene therapies, with lifetime…
PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
Investing in Leaders and Capabilities That Help Health Plans Succeed DALLAS, TX – April 1, 2026 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, announced…
